Literature DB >> 20683659

Rates of surveillance and management of hepatocellular carcinoma in patients evaluated at a liver transplant center.

Janice H Jou1, Po-Hung Chen, Alison Jazwinski, Iliana Bouneva, Alastair D Smith, Andrew J Muir.   

Abstract

OBJECTIVES: The treatment of choice for HCC with cirrhosis is liver transplantation (LT). We assessed if patients evaluated for hepatocellular carcinoma are being diagnosed by surveillance, the proportion of patients meeting Milan criteria at diagnosis, and rates of liver transplantation.
METHODS: All HCC cases in cirrhotic patients at Duke University Medical Center in the MELD era (Feb 2002-Oct 2008) were identified. Surveillance was defined as an imaging exam for detection of HCC in the 12 months prior to diagnosis of HCC. Logistic regression was used to examine predictors of LT.
RESULTS: There were 319 cases meeting diagnostic criteria for HCC. Only 30.7% were diagnosed by surveillance and 43.7% met Milan criteria at diagnosis. Patients diagnosed by surveillance were more likely to meet Milan criteria and to receive LT (p < 0.0001 for both outcomes). Surveillance was associated with higher rates of LT with an OR 2.6 (95% CI 1.2-5.7, p = 0.02). Patients managed by a hepatologist were more likely to be diagnosed by surveillance (65.9 vs. 19.0%, p < 0.0001). Patients meeting Milan criteria managed by a hepatologist were more likely to receive LT than those referred from other providers (26.4 vs. 8%, p = 0.009).
CONCLUSIONS: A minority of HCC cases in cirrhotic patients were diagnosed by surveillance, and only 12.5% underwent LT. Patients diagnosed by surveillance were more likely to meet Milan criteria and to undergo LT. These findings highlight the need for increased identification of patients with chronic liver disease and for subsequent referral to hepatologists for enrollment in HCC surveillance programs.

Entities:  

Mesh:

Year:  2010        PMID: 20683659      PMCID: PMC5144159          DOI: 10.1007/s10620-010-1366-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

Review 2.  Hepatocellular carcinoma and hepatitis C in the United States.

Authors:  Hashem B El-Serag
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 3.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

4.  Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

Authors:  Franco Trevisani; Stefania De Notariis; Gianludovico Rapaccini; Fabio Farinati; Luisa Benvegnù; Marco Zoli; Gian Luca Grazi; Poggio Paolo Del; NolfoMariaAnna Di; Mauro Bernardi
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

5.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

6.  Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic.

Authors:  Myron J Tong; Hai-En Sun; Carlos Hsien; David S K Lu
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

7.  Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.

Authors:  George N Ioannou; James D Perkins; Robert L Carithers
Journal:  Gastroenterology       Date:  2008-02-13       Impact factor: 22.682

8.  Utilization of screening for hepatocellular carcinoma in the United States.

Authors:  Jessica A Davila; Allan Weston; Walter Smalley; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2007-09       Impact factor: 3.062

9.  Improving access to care by allowing self-referral to a hepatitis C clinic.

Authors:  K E Doucette; V Robson; S Shafran; D Kunimoto
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

10.  Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.

Authors:  Richard Todd Stravitz; Douglas M Heuman; Nisha Chand; Richard K Sterling; Mitchell L Shiffman; Velimir A Luketic; Arun J Sanyal; Adil Habib; Anastasios A Mihas; Ho-Chong S Giles; Daniel G Maluf; Adrian H Cotterell; Marc P Posner; Robert A Fisher
Journal:  Am J Med       Date:  2008-02       Impact factor: 4.965

View more
  5 in total

Review 1.  Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.

Authors:  Pei-Pei Song; Ju-Feng Xia; Yoshinori Inagaki; Kiyoshi Hasegawa; Yoshihiro Sakamoto; Norihiro Kokudo; Wei Tang
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 2.  Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review.

Authors:  Amit G Singal; Adam Yopp; Celette S Skinner; Milton Packer; William M Lee; Jasmin A Tiro
Journal:  J Gen Intern Med       Date:  2012-01-04       Impact factor: 5.128

Review 3.  Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States.

Authors:  D Tan; A Yopp; M S Beg; P Gopal; A G Singal
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

4.  Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk?

Authors:  Danielle M Tholey; Ben Hornung; Charles K Enestvedt; Yiyi Chen; Willscott S Naugler; Khashayar Farsad; Nima Nabavizadeh; Barry Schlansky; Joseph Ahn; Janice H Jou
Journal:  BMJ Open Gastroenterol       Date:  2017-09-11

5.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.